MIM
KYMR icon

MetLife Investment Management’s Kymera Therapeutics KYMR Stock Holding History

MetLife Investment Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Buy
36,494
+4,987
+16% +$428K 0.02% 750
2026
Q1 		$2.62M Buy
31,507
+113
+0.4% +$8.95K 0.01% 920
2025
Q4 		$2.44M Buy
31,394
+1,895
+6% +$128K 0.01% 978
2025
Q3 		$1.67M Buy
29,499
+1,712
+6% +$77.2K 0.01% 1181
2025
Q2 		$1.21M Hold
27,787
– – 0.01% 1214
2025
Q1 		$761K Sell
27,787
-424
-2% -$15.5K ﹤0.01% 1498
2024
Q4 		$1.13M Buy
28,211
+2,323
+9% +$105K 0.01% 1347
2024
Q3 		$1.23M Hold
25,888
– – 0.01% 1277
2024
Q2 		$773K Buy
25,888
+5,134
+25% +$178K ﹤0.01% 1491
2024
Q1 		$834K Buy
20,754
+789
+4% +$28.2K 0.01% 1399
2023
Q4 		$508K Hold
19,965
– – ﹤0.01% 1674
2023
Q3 		$278K Hold
19,965
– – ﹤0.01% 2004
2023
Q2 		$459K Hold
19,965
– – ﹤0.01% 1753
2023
Q1 		$592K Hold
19,965
– – ﹤0.01% 1541
2022
Q4 		$498K Sell
19,965
-2,273
-10% -$60.6K ﹤0.01% 1650
2022
Q3 		$484K Buy
22,238
+3,010
+16% +$79.3K ﹤0.01% 1659
2022
Q2 		$379K Hold
19,228
– – ﹤0.01% 1856
2022
Q1 		$814K Buy
19,228
+6,981
+57% +$295K 0.01% 1464
2021
Q4 		$778K Hold
12,247
– – 0.01% 1247
2021
Q3 		$719K Buy
12,247
+1,063
+10% +$61.6K 0.01% 1311
2021
Q2 		$542K Buy
11,184
+6,635
+146% +$288K ﹤0.01% 1522
2021
Q1 		$177K Hold
4,549
– – ﹤0.01% 2122
2020
Q4 		$282K Buy
+4,549
New +$222K ﹤0.01% 1799

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

MetLife Investment Management's KYMR Position: Q2 2026 in Review

MetLife Investment Management increased its Kymera Therapeutics (KYMR) stake by 16% in Q2 2026, buying an estimated $428K and bringing the position to 36,494 shares worth $4.18M. The position accounts for 0.02% of the portfolio, ranked #750.

MetLife Investment Management first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • MetLife Investment Management held 36,494 shares of Kymera Therapeutics worth $4.18M as of Q2 2026.
  • MetLife Investment Management bought 4,987 Kymera Therapeutics shares in Q2 2026, an estimated $428K.
  • Kymera Therapeutics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #750 holding.
  • MetLife Investment Management first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.